The Latin America, Middle East and Africa Cardiac Biomarkers Testing Market would witness market growth of 12.4% CAGR during the forecast period (2019?2025). Conventional laboratory tests use cardiac biomarkers to examine the cardiac anomalies that result in cardiac arrest and ACS. Since these laboratories focus on providing reliable and accurate results, the vendors are increasingly concentrating on developing cardiac biomarkers for laboratory services. Hospitals make use of cardiac biomarkers to rapidly detect myocardial necrosis and to increase the survival rate of patients. Hospitals and specialty clinics use cardiac biomarkers for imaging procedures for cardiology to detect the level of anomalies which may lead to heart failure. Specialty clinics offer specialized health packages at reduced costs for imaging services for patients suffering from diabetes accompanied by cardiac abnormalities.
Based on Type, the market is segmented into Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP and NT-proBNP), Ischemia Modified Albumin and Others. Based on Application, the market is segmented into Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis and Others. Based on Location of Testing, the market is segmented into Point of Care Testing and Laboratory Testing. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Trivitron Healthcare Pvt. Ltd., ABBOTT Laboratories, Siemens AG, Becton, Dickinson AND Company, Bio-Rad laboratories, Inc., Randox Laboratories Limited, Danaher Corporation, Thermo Fisher Scientific, Inc., Johnson and Johnson and Quidel Corporation.
Market Segmentation:
By Type
By Application
By Location of Testing
By Country
Companies Profiled
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.